[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | News | More
or
Your Free 7-Day Premier trial ends on . Extend Your Trial For Another 30 Days. Time remaining
Faster, Cleaner, Better.

Trevi Therapeutics Inc (TRVI)

Trevi Therapeutics Inc (TRVI)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 2,365,102
  • Shares Outstanding, K 142,476
  • Annual Sales, $ 0 K
  • Annual Income, $ -42,760 K
  • EBIT $ -60 M
  • EBITDA $ -59 M
  • 60-Month Beta 1.03
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 7.41

Options Overview Details

View History
  • Implied Volatility 45.98% (-0.04%)
  • Historical Volatility 36.36%
  • IV Percentile 3%
  • IV Rank 3.60%
  • IV High 263.53% on 02/18/26
  • IV Low 37.85% on 08/26/26
  • Expected Move (DTE 17) 0.43 (2.56%)
  • Put/Call Vol Ratio 0.20
  • Today's Volume 59
  • Volume Avg (30-Day) 1,102
  • Put/Call OI Ratio 0.16
  • Today's Open Interest 19,542
  • Open Int (30-Day) 17,572
  • Expected Range 16.15 to 17.00

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 14 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/26
See More
  • Average Estimate $-0.13
  • Number of Estimates 6
  • High Estimate $-0.11
  • Low Estimate $-0.15
  • Prior Year $-0.08
  • Growth Rate Est. (year over year) -62.50%

Price Performance

See More
Period Period Low Period High Performance
1-Month
16.08 +3.05%
on 08/31/26
19.30 -14.15%
on 08/19/26
-1.68 (-9.21%)
since 07/31/26
3-Month
13.20 +25.53%
on 06/09/26
20.22 -18.05%
on 07/17/26
+2.62 (+18.78%)
since 06/01/26
52-Week
6.93 +139.11%
on 09/05/25
20.22 -18.05%
on 07/17/26
+9.31 (+128.39%)
since 08/29/25

Most Recent Stories

More News
Trevi Therapeutics Announces Upcoming Presentations at the European Respiratory Society (ERS) Congress 2026

Professor Marlies Wijsenbeek will give an oral presentation on the quality-of-life outcomes assessed by the LCQ from the Phase 2b CORAL trial of nalbuphine ER for the treatment of patients with IPF-related...

TRVI : 16.57 (-0.18%)
Trevi Therapeutics Announces Upcoming Presentations at the European Respiratory Society (ERS) Congress 2026

Professor Marlies Wijsenbeek will give an oral presentation on the quality-of-life outcomes assessed by the LCQ from the Phase 2b CORAL trial of nalbuphine ER for the treatment of patients with IPF-related...

TRVI : 16.57 (-0.18%)
Trevi Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Updates

Initiated Phase 3 OCEAN-1 trial for patients with idiopathic pulmonary fibrosis-related chronic cough in the second quarter; Phase 3 OCEAN-2 trial expected to initiate in the third quarter of 2026 ...

TRVI : 16.57 (-0.18%)
Trevi Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Updates

Initiated Phase 3 OCEAN-1 trial for patients with idiopathic pulmonary fibrosis-related chronic cough in the second quarter; Phase 3 OCEAN-2 trial expected to initiate in the third quarter of 2026

TRVI : 16.57 (-0.18%)
Trevi Therapeutics' Chronic Cough Pipeline Faces Its First Investor Scrutiny Since Conference Season

Barchart Research What to Expect from TRVI Earnings TRVI Generated August 5, 2026 Current Price $18.65 EPS Estimate $$-0.11 Consensus Rating Strong Buy Average Move 2.75% Trevi Therapeutics' Chronic Cough...

TRVI : 16.57 (-0.18%)
Trevi Therapeutics to Report Second Quarter 2026 Financial Results and Provide a Corporate Update on August 6, 2026

NEW HAVEN, Conn., July 30, 2026 (GLOBE NEWSWIRE) -- Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphine...

TRVI : 16.57 (-0.18%)
Trevi Therapeutics to Participate in Upcoming August Conferences

NEW HAVEN, Conn., July 28, 2026 (GLOBE NEWSWIRE) -- Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphine...

TRVI : 16.57 (-0.18%)
Trevi Therapeutics to Participate in Upcoming August Conferences

NEW HAVEN, Conn., July 28, 2026 (GLOBE NEWSWIRE) -- Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphine...

TRVI : 16.57 (-0.18%)
Trevi Therapeutics Announces Upcoming June and July Event Schedule  

NEW HAVEN, Conn., June 17, 2026 (GLOBE NEWSWIRE) -- Trevi Therapeutics, Inc.  (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral...

TRVI : 16.57 (-0.18%)
Trevi Therapeutics Announces Upcoming June and July Event Schedule

NEW HAVEN, Conn., June 17, 2026 (GLOBE NEWSWIRE) -- Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the...

TRVI : 16.57 (-0.18%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 40% Buy with a Weakest short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Trevi Therapeutics Inc. is a clinical-stage biopharmaceutical company. It is focused on the development and commercialization of nalbuphine ER to treat serious neurologically mediated conditions. The company is currently developing nalbuphine ER for the treatment of chronic pruritus, chronic cough in...

See More

Key Turning Points

3rd Resistance Point 17.17
2nd Resistance Point 16.95
1st Resistance Point 16.76
Last Price 16.57
1st Support Level 16.35
2nd Support Level 16.13
3rd Support Level 15.94

See More

52-Week High 20.22
Last Price 16.57
Fibonacci 61.8% 15.14
Fibonacci 50% 13.57
Fibonacci 38.2% 12.01
52-Week Low 6.93

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.